[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.166.112.64. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
November 10, 1989

Photodynamic Therapy Triggers Cytotoxic Drug Retained to Greater Degree by Cancer Cells

Author Affiliations

Editor, Pulse

Editor, Pulse

JAMA. 1989;262(18):2500. doi:10.1001/jama.1989.03430180018003

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.

Abstract

RESEARCHERS ARE hoping that the triple threat of light, oxygen, and light-sensitive drugs will usher in a new age in cancer treatment. The new weapon, called photodynamic therapy, uses laser light to activate a cytotoxic drug selectively in tumor cells.

The drugs involved, hematoporphyrin and its more potent derivative, dihematoporphyrin ether (DHE, Photofrin) (Quadra Logic Technologies, Vancouver, Canada), have been known to be light activated since early in this century. But it was not until the 1970s that the first systemic use of photodynamic therapy was pioneered by Thomas Dougherty, PhD, and his group at Roswell Park Memorial Institute, the New York State facility in Buffalo.

The drug enters both normal and malignant cells. However, it is retained to a greater degree by neoplastic cells.

Thus, 48 to 72 hours after administration, there is a gradient between the normal cells and the tumor. Photodynamic therapy seeks to exploit this.

The

×